BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36116741)

  • 1. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer.
    Shen D; Luo J; Chen L; Ma W; Mao X; Zhang Y; Zheng J; Wang Y; Wan J; Wang S; Ouyang J; Yi H; Liu D; Huang W; Zhang W; Liu Z; McLeod HL; He Y
    Cancer Lett; 2022 Dec; 550():215919. PubMed ID: 36116741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer.
    Storozynsky Q; Hitt MM
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
    Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
    J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway.
    Dong Q; Yu T; Chen B; Liu M; Sun X; Cao H; Liu K; Xu H; Wang Y; Zhuang S; Jin Z; Liang H; Hui Y; Gu Y
    JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy.
    Liang JL; Jin XK; Zhang SM; Huang QX; Ji P; Deng XC; Cheng SX; Chen WH; Zhang XZ
    Sci Bull (Beijing); 2023 Mar; 68(6):622-636. PubMed ID: 36914548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade.
    Wang M; Huang Y; Chen M; Wang W; Wu F; Zhong T; Chen X; Wang F; Li Y; Yu J; Wu M; Chen D
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37620043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer.
    Wang T; Liu W; Shen Q; Tao R; Li C; Shen Q; Lin Y; Huang Y; Yang L; Xie G; Bai J; Li R; Wang L; Tao K; Yin Y
    Cancer Sci; 2023 Nov; 114(11):4184-4201. PubMed ID: 37702298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
    Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
    Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
    J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity.
    Li GL; Ding GX; Zeng L; Ming SL; Fu PF; Wang Q; Yang GY; Wang J; Chu BB
    J Virol; 2021 Jul; 95(16):e0076021. PubMed ID: 34037418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling.
    Oh G; Wang A; Wang L; Li J; Werba G; Weissinger D; Zhao E; Dhara S; Hernandez RE; Ackermann A; Porcella S; Kalfakakou D; Dolgalev I; Kawaler E; Golan T; Welling TH; Sfeir A; Simeone DM
    J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 36976649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cGAS-STING-mediated DNA sensing maintains CD8
    Li W; Lu L; Lu J; Wang X; Yang C; Jin J; Wu L; Hong X; Li F; Cao D; Yang Y; Wu M; Su B; Cheng J; Yang X; Di W; Deng L
    Sci Transl Med; 2020 Jun; 12(549):. PubMed ID: 32581136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
    Seyedin SN; Hasibuzzaman MM; Pham V; Petronek MS; Callaghan C; Kalen AL; Mapuskar KA; Mott SL; Spitz DR; Allen BG; Caster JM
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):81-92. PubMed ID: 32036006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
    Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
    Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple Tumor Microenvironment-Responsive Ferroptosis Pathways Induced by Manganese-Based Imageable Nanoenzymes for Enhanced Breast Cancer Theranostics.
    He H; Du L; Xue H; An Y; Zeng K; Huang H; He Y; Zhang C; Wu J; Shuai X
    Small Methods; 2023 Jul; 7(7):e2300230. PubMed ID: 37096886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.